A new 8.6mg/2.1mg dosage strength of Zubsolv (buprenorphine/naloxone) is now available. Manufacturer Orexo received FDA approval for the new dosage as maintenance treatment of opioid dependence, used as part of a comprehensive treatment plan, which includes counseling and psychosocial support.
Zubsolv sublingual tablets deliver a greater proportion of active ingredient to the bloodstream than other older sublingual products, allowing patients to use a lower strength thereby reducing the amount of available drug for potential misuse. Tablets are also available in strengths of 5.7 mg/1.4 mg and 1.4 mg/0.36 mg. Treatment should be initiated under the direction of physicians who are certified under the Drug Addiction Treatment Act of 2000.
In a press release, Robert DeLuca, R.Ph., president of Orexo, said the additional strength improves the ability for physicians and patients to individualize treatment plans.
Further information on Zubsolv can be found at www.zubsolv.com.